Mixed Pathology Effects on Parkinson's Disease Progression and Treatment Response

V2, Crosslink

🧫

Mixed Pathology Effects on Parkinson's Disease Progression and Treatment Response

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-mixed-pa

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Mixed Pathology Effects on Parkinson's Disease Progression and Treatment Response ## Background and Rationale This clinical study investigates the impact of mixed pathology—specifically concurrent Alzheimer's disease (AD) and Parkinson's disease (PD) pathology—on disease progression and treatment response in patients with parkinsonism. Growing evidence suggests that up to 50% of PD patients develop AD-related pathology, including amyloid plaques and tau tangles, which may accelerate cognitive

METHODOLOGY NOTES

Phase 1 (Months 0-3): Recruit 450 participants across three cohorts (150 each): pure PD, pure AD, and mixed pathology patients. Conduct comprehensive baseline assessments including neurological examinations, cognitive testing (MoCA, MMSE), motor evaluations (UPDRS-III), and quality of life measures. Obtain CSF samples for biomarker analysis and perform baseline neuroimaging (18F-flutemetamol PET, DaTscan, structural MRI). Phase 2 (Months 3-24): Implement standardized treatment protocols—levodopa/carbidopa for PD symptoms, cholinesterase inhibitors for cognitive symptoms. Conduct quarterly follow-up assessments measuring cognitive decline rates, motor symptom progression, and treatment response. Monitor adverse events and medication adherence. Phase 3 (Months 24-36): Continue longitudinal tracking with biannual assessments. Perform repeat neuroimaging at 18 and 36 months. Collect additional CSF samples at 12-month intervals. Analyze treatment response patterns, progression rates, and bi

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.897603Z'}
summary	# Mixed Pathology Effects on Parkinson's Disease Progression and Treatment Response ## Background and Rationale This clinical study investigates the impact of mixed pathology—specifically concurrent A
entities	{'genes': ['BCL2L1/C1Q/C3'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Mixed Pathology Effects on Parkinson's Disease Progression and Treatment Response
methodology_notes	Phase 1 (Months 0-3): Recruit 450 participants across three cohorts (150 each): pure PD, pure AD, and mixed pathology patients. Conduct comprehensive baseline assessments including neurological examin
replication_status	replicated
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.897608', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

648

Outgoing

621

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mixed Pathology Effects on Parkinson's Disease Progression and Treatment Response

derives from (16)

supports (5)

💬 Discussion